Welcome to Sussex Health Outcomes
Research & Education in Cancer

Research PublicationsContact Us

The central aim of Sussex Health Outcomes, Research & Education in Cancer (SHORE-C) is to conduct pragmatic research in psychosocial oncology.

Our work includes:

  1. Measuring Quality of Life (QoL) in clinical trials of cancer therapy

  2. Designing Patient Reported Outcome (PRO) measures

  3. Developing and evaluating interventions to help patients deal with treatment side-effects

  4. Producing educational materials and helping to improve communication skills of Cancer Healthcare Professionals

^ Top


Too hot, too cold or can we get it just right? What emotional distance should oncologists keep from their patients? Read morered arrow

Patient-reported outcome measures of the impact of cancer on patients’ everyday lives: a systematic review. Read morered arrow

Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. Read morered arrow

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC3). Simultaneously published in Annals of Oncology and The Breast. Read morered arrow

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Read morered arrow

Sexual dysfunction in breast cancer survivors: cross-cultural adaptation of the Sexual Activity Questionnaire for use in Portugal. Read morered arrow

Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guidelines Read morered arrow

Therapeutic aims of drugs offering only progression-free survival are
misunderstood by patients, and oncologists may be overly optimistic about likely benefits. Read morered arrow

Ovarian Cancer in Nature Reviews Disease Primers (restricted access) Read morered arrow

No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer. Read morered arrow

Patient-reported outcomes in metastatic castrate-resistant prostate cancer.
Read morered arrow

Essay 4. Patient-reported outcome measures and the evaluation of services in Challenges, solutions and future directions in the evaluation of service innovations in health care and public health.
Read morered arrow

^ Top



Dr Val Shilling presented a PROACT poster at the International Society for Quality of Life Research (ISOQOL) 23rd Annual Conference in Copenhagen, Denmark. Read more on the PROACT page.

Rachel Starkings also presented this poster at the Inaugural Postdoctoral Research Day on the 2nd of November 2016. The poster explored the first two phases of the PROACT study and was awarded first prize on the day. More information on the study can be found on the PROACT page.

Photo: Dr Val Shilling

'For services to psycho-oncology' lecture on YouTube

It was a full house for Professor Dame Lesley Fallowfield's lecture 'For services to psycho-oncology' Psycho what?' which took place on 22 September 2016.

Dame Lesley gave a fascinating account of her career to date alongside a parallel history of the field of psycho oncology.  

A video of the lecture is now available on YouTube for those who missed the event via this link For services to psycho-oncology

Photo: BSMS Dean Malcolm Reed and University of Sussex VC Prof Adam Tickell with Dame Lesley

New Grant Award

Professor Dame Lesley Fallowfield has been awarded a prestigious Breast Cancer Research Foundation (BCRF) grant of $250,000 annually.

The BCRF is the highest rated breast cancer organisation in the US and eminent researchers are invited to apply for funding. Dame Lesley proposed two distinct projects.

One is to produce a communication-skills DVD/workshop for clinicians discussing genomic test results with breast cancer patients; the other working with Dr Melanie Flint at Brighton University and UK breast oncologists, will examine the psycho-neuroimmunological and biological factors underpinning personalised supportive interventions for women with breast cancer.

More news ...

^ Top